Pharmaceutical / Drug Definition :
Inhibits triglyceride synthesis in liver, reducing levels of low- and very-low-density lipoproteins. Also increases uric acid secretion.
FDA Detentions
Fenofibrate (Fenofibrate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Fenofibrate (Fenofibrate Suppliers)
- Processors Fenofibrate
- Repackers Fenofibrate
- Relabelers Fenofibrate
- Exporters Fenofibrate
- Importers Fenofibrate
For more information about Fenofibrate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.
